ikcs 2020: phase 2 trial of lenvatinib at 2 starting doses everolimus in renal cell carcinoma (rcc)
Published 3 years ago • 464 plays • Length 10:55Download video MP4
Download video MP3
Similar videos
-
1:32
phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma
-
1:19
phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma
-
50:08
ikcs 2020: non-clear cell rcc session
-
4:28
metastatic renal cell carcinoma: lenvatinib phase ii data
-
1:32
three-arm trial of lenvatinib and everolimus for metastatic renal cell carcinoma
-
1:01:19
ikcs 2020: session 1: multimodality therapy for locally advanced rcc
-
0:45
dr. choueiri on fda approval of lenvatinib/everolimus in rcc
-
5:32
lenvatinib and everolimus for advanced rcc
-
2:37
lenvatinib/everolimus in refractory mrcc
-
1:33:22
ikcs 2020: session 3 immunotherapy and emerging therapies for rcc
-
2:40
efficacy and safety of lenvatinib/everolimus in mrcc
-
6:22
mtor/tki combination therapy in kidney cancer
-
38:09
understanding and working with new immunotherapeutic and targeted management models in advanced rcc
-
1:14
dr. larkin on lenvatinib plus everolimus in patients with rcc
-
0:47
phase 2 trial shows antitumor activity in metastatic clear cell rcc
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
1:15
q-twist of lenvatinib everolimus in advanced rcc
-
0:49
clear: lenvatinib and pembrolizumab in advanced renal cell carcinoma
-
1:22
discussing the phase ii study of lenvatinib/pembrolizumab in metastatic ccrcc